TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT06042257

Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)

Cause of deathFunding or business, also drug or device supply Automatic label, confidence 0.5, unverified. How labels are made.
“Study was stopped after careful review of product manufacturing needs and available resources. Decision reflects consideration of feasibility, enrollment challenges, and overall program goals.”

The sponsor’s own words in the registry.

Life of this trial

2023202420252026Registered2023-07-31Started2024-12-09Primary completion2025-05-17Stopped2025-08-12

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
Rachel G. Greenberg, MD, MB, MHS
Sponsor type
University, hospital or other
Conditions
Hyperactivity in Children With Down Syndrome; Impulsivity in Children With Down Syndrome
Interventions
Guanfacine Hydrochloride Immediate Release; Placebo
Participants
3
Sites
14
Countries
United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.